SenesTech CEO Joel Fruendt Announces Retirement
SenesTech announced that Joel Fruendt, President and CEO, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, whichever occurs first. In addition, to further support this transition, the Board has appointed Dr. Jamie Bechtel, current Chair of the Board, to the newly created role of Interim Executive Chair.
Trade with 70% Backtested Accuracy
Analyst Views on SNES
No data
About SNES
About the author
SenesTech Schedules Q4 and FY 2025 Financial Results Release
- Financial Results Announcement: SenesTech is set to release its financial results for Q4 and FY 2025 after market close on March 12, 2026, reflecting the company's ongoing commitment to managing rodent populations through innovative birth control solutions.
- Conference Call Timing: On the same day, a conference call will be held at 5:00 p.m. ET to discuss the financial results in detail, aiming to bolster investor confidence in the company's future prospects.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available in the Investor Relations section of the company's website, ensuring transparency and fostering engagement with investors, thereby enhancing the company's public image.
- Replay Availability: A replay of the webcast will be accessible in the Investor Relations section for at least 90 days post-conference, allowing investors who could not attend live to obtain critical information, thus improving information accessibility.
SenesTech Schedules Q4 and FY 2025 Financial Results Release
- Financial Results Announcement: SenesTech is set to release its fourth quarter and fiscal year 2025 financial results after market close on March 12, 2026, reflecting the company's ongoing commitment to financial transparency.
- Conference Call Timing: On the same day, a conference call will be held at 5:00 p.m. ET to analyze the financial results in depth and engage with investors, thereby enhancing investor relations.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available in the Investor Relations section of the company's website, ensuring broad dissemination and transparency of information.
- Replay Availability: A replay of the webcast will be accessible in the Investor Relations section for at least 90 days post-conference, further improving information accessibility and company transparency.
SenesTech's Evolve Rodent Birth Control Shows Significant Reduction in Rodent Activity
- Urban Rodent Management Success: Following the deployment of Evolve® Rodent Birth Control in two urban areas, SenesTech reported significant reductions in rodent activity over a five-month monitoring period, indicating the product's effectiveness in urban environments.
- Monitoring Data Support: In the first area, where Evolve was deployed starting in April 2025, tracking data from August 2025 to January 2026 showed declines in both rodent presence and activity levels, despite the absence of baseline data, highlighting the product's positive impact.
- Comparative Trial Results: In the second area, Evolve was deployed immediately after an August 2025 baseline survey, resulting in measurable reductions in rodent activity within five months, based on both presence and density indicators, further validating the product's efficacy.
- Industry Impact and Outlook: CEO Joel Fruendt emphasized that objective field data is critical for municipalities and pest management professionals evaluating fertility control as part of broader integrated pest management programs, potentially driving future expansions into new locations.
SenesTech Launches Evolve to Support New Zealand's Predator Free 2050 Initiative
- Product Approval: SenesTech's Evolve has been approved by New Zealand's Ministry for Primary Industries, marking its official launch in the market and is expected to effectively address local rodent issues while enhancing ecological protection efforts.
- Ecological Protection Strategy: New Zealand plans to invest over NZD 4.5 billion in its Predator Free 2050 initiative, and Evolve, as a non-lethal fertility control solution, will help reduce rodent populations, safeguarding native species and ecosystems.
- Market Demand Alignment: CEO Joel Fruendt stated that Evolve aligns with New Zealand's increasingly stringent environmental policies and regulatory standards, meeting the urgent market demand for sustainable alternatives to traditional rodenticides, thereby enhancing the company's leadership in high-growth markets.
- Ongoing Supply Chain: SenesTech has shipped to its exclusive distribution partner Evicom and expects to maintain a regular shipping schedule, ensuring a stable supply of Evolve products and further solidifying its influence in the New Zealand market.
SenesTech Expands International Reach with the Addition of the Belize Raptor Center as an Official Distributor of Evolve® Rat Birth Control
Introduction of Evolve® Rat Birth Control: SenesTech, Inc. has partnered with Sarah Mann and the Belize Raptor Center to introduce Evolve® Rat Birth Control in Belize, aiming to manage rodent populations humanely and sustainably amidst rising concerns over toxic rodenticides.
Ecological Impact and Education Campaign: The initiative addresses the ecological threats posed by unregulated rodenticides, launching a grassroots education campaign to inform the public about the dangers of these poisons and promote fertility control as a safer alternative.
SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA
Financial Performance: SenesTech reported a 43% increase in revenues for Q3 2025, reaching $690,000, with Evolve® Rodent Birth Control™ products driving a 77% year-over-year growth, now accounting for 85% of total revenue.
Operational Highlights: The company saw significant growth in various channels, including a 139% increase in municipal revenue and a 254% rise in retail revenue, supported by expanded partnerships and e-commerce sales.
Profitability Progress: Despite a net loss of $1.3 million, the adjusted EBITDA loss improved to $1.2 million, indicating progress towards profitability, bolstered by a strong cash balance of $10.2 million.
Strategic Outlook: CEO Joel Fruendt emphasized the company's commitment to pursuing profitable growth and expanding its innovative pest control product line, aiming for breakeven and long-term market potential.
SenesTech Schedules Q4 and FY 2025 Financial Results Release
- Financial Results Announcement: SenesTech is set to release its financial results for Q4 and FY 2025 after market close on March 12, 2026, reflecting the company's ongoing commitment to managing rodent populations through innovative birth control solutions.
- Conference Call Timing: On the same day, a conference call will be held at 5:00 p.m. ET to discuss the financial results in detail, aiming to bolster investor confidence in the company's future prospects.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available in the Investor Relations section of the company's website, ensuring transparency and fostering engagement with investors, thereby enhancing the company's public image.
- Replay Availability: A replay of the webcast will be accessible in the Investor Relations section for at least 90 days post-conference, allowing investors who could not attend live to obtain critical information, thus improving information accessibility.
SenesTech Schedules Q4 and FY 2025 Financial Results Release
- Financial Results Announcement: SenesTech is set to release its fourth quarter and fiscal year 2025 financial results after market close on March 12, 2026, reflecting the company's ongoing commitment to financial transparency.
- Conference Call Timing: On the same day, a conference call will be held at 5:00 p.m. ET to analyze the financial results in depth and engage with investors, thereby enhancing investor relations.
- Live Webcast Information: Interested parties can access the conference call via a live webcast available in the Investor Relations section of the company's website, ensuring broad dissemination and transparency of information.
- Replay Availability: A replay of the webcast will be accessible in the Investor Relations section for at least 90 days post-conference, further improving information accessibility and company transparency.
SenesTech's Evolve Rodent Birth Control Shows Significant Reduction in Rodent Activity
- Urban Rodent Management Success: Following the deployment of Evolve® Rodent Birth Control in two urban areas, SenesTech reported significant reductions in rodent activity over a five-month monitoring period, indicating the product's effectiveness in urban environments.
- Monitoring Data Support: In the first area, where Evolve was deployed starting in April 2025, tracking data from August 2025 to January 2026 showed declines in both rodent presence and activity levels, despite the absence of baseline data, highlighting the product's positive impact.
- Comparative Trial Results: In the second area, Evolve was deployed immediately after an August 2025 baseline survey, resulting in measurable reductions in rodent activity within five months, based on both presence and density indicators, further validating the product's efficacy.
- Industry Impact and Outlook: CEO Joel Fruendt emphasized that objective field data is critical for municipalities and pest management professionals evaluating fertility control as part of broader integrated pest management programs, potentially driving future expansions into new locations.
SenesTech Launches Evolve to Support New Zealand's Predator Free 2050 Initiative
- Product Approval: SenesTech's Evolve has been approved by New Zealand's Ministry for Primary Industries, marking its official launch in the market and is expected to effectively address local rodent issues while enhancing ecological protection efforts.
- Ecological Protection Strategy: New Zealand plans to invest over NZD 4.5 billion in its Predator Free 2050 initiative, and Evolve, as a non-lethal fertility control solution, will help reduce rodent populations, safeguarding native species and ecosystems.
- Market Demand Alignment: CEO Joel Fruendt stated that Evolve aligns with New Zealand's increasingly stringent environmental policies and regulatory standards, meeting the urgent market demand for sustainable alternatives to traditional rodenticides, thereby enhancing the company's leadership in high-growth markets.
- Ongoing Supply Chain: SenesTech has shipped to its exclusive distribution partner Evicom and expects to maintain a regular shipping schedule, ensuring a stable supply of Evolve products and further solidifying its influence in the New Zealand market.
SenesTech Expands International Reach with the Addition of the Belize Raptor Center as an Official Distributor of Evolve® Rat Birth Control
Introduction of Evolve® Rat Birth Control: SenesTech, Inc. has partnered with Sarah Mann and the Belize Raptor Center to introduce Evolve® Rat Birth Control in Belize, aiming to manage rodent populations humanely and sustainably amidst rising concerns over toxic rodenticides.
Ecological Impact and Education Campaign: The initiative addresses the ecological threats posed by unregulated rodenticides, launching a grassroots education campaign to inform the public about the dangers of these poisons and promote fertility control as a safer alternative.
SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA
Financial Performance: SenesTech reported a 43% increase in revenues for Q3 2025, reaching $690,000, with Evolve® Rodent Birth Control™ products driving a 77% year-over-year growth, now accounting for 85% of total revenue.
Operational Highlights: The company saw significant growth in various channels, including a 139% increase in municipal revenue and a 254% rise in retail revenue, supported by expanded partnerships and e-commerce sales.
Profitability Progress: Despite a net loss of $1.3 million, the adjusted EBITDA loss improved to $1.2 million, indicating progress towards profitability, bolstered by a strong cash balance of $10.2 million.
Strategic Outlook: CEO Joel Fruendt emphasized the company's commitment to pursuing profitable growth and expanding its innovative pest control product line, aiming for breakeven and long-term market potential.
